These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1083 related items for PubMed ID: 16463007

  • 1. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
    Lems WF, Lodder MC, Lips P, Bijlsma JW, Geusens P, Schrameijer N, van de Ven CM, Dijkmans BA.
    Osteoporos Int; 2006; 17(5):716-23. PubMed ID: 16463007
    [Abstract] [Full Text] [Related]

  • 2. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.
    Khan AA, Bilezikian JP, Kung AW, Ahmed MM, Dubois SJ, Ho AY, Schussheim D, Rubin MR, Shaikh AM, Silverberg SJ, Standish TI, Syed Z, Syed ZA.
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3319-25. PubMed ID: 15240609
    [Abstract] [Full Text] [Related]

  • 3. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
    Tascioglu F, Colak O, Armagan O, Alatas O, Oner C.
    Rheumatol Int; 2005 Nov; 26(1):21-9. PubMed ID: 15688191
    [Abstract] [Full Text] [Related]

  • 4. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ, MK-677/Alendronate Study Group.
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [Abstract] [Full Text] [Related]

  • 5. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial.
    Chevrel G, Schott AM, Fontanges E, Charrin JE, Lina-Granade G, Duboeuf F, Garnero P, Arlot M, Raynal C, Meunier PJ.
    J Bone Miner Res; 2006 Feb; 21(2):300-6. PubMed ID: 16418786
    [Abstract] [Full Text] [Related]

  • 6. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
    Biermasz NR, Hamdy NA, Janssen YJ, Roelfsema F.
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
    [Abstract] [Full Text] [Related]

  • 7. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [Abstract] [Full Text] [Related]

  • 8. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB.
    J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
    [Abstract] [Full Text] [Related]

  • 9. Effects of a combined alendronate and calcitriol agent (Maxmarvil) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study.
    Rhee Y, Kang M, Min Y, Byun D, Chung Y, Ahn C, Baek K, Mok J, Kim D, Kim D, Kim H, Kim Y, Myoung S, Kim D, Lim SK.
    Osteoporos Int; 2006 Dec; 17(12):1801-7. PubMed ID: 17019520
    [Abstract] [Full Text] [Related]

  • 10. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
    Klotz LH, McNeill IY, Kebabdjian M, Zhang L, Chin JL, Canadian Urology Research Consortium.
    Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208
    [Abstract] [Full Text] [Related]

  • 11. Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis.
    Jacobs JW, de Nijs RN, Lems WF, Geusens PP, Laan RF, Huisman AM, Algra A, Buskens E, Hofbauer LC, Oostveen AC, Bruyn GA, Dijkmans BA, Bijlsma JW.
    J Rheumatol; 2007 May; 34(5):1051-7. PubMed ID: 17407214
    [Abstract] [Full Text] [Related]

  • 12. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
    Bonnick S, Broy S, Kaiser F, Teutsch C, Rosenberg E, DeLucca P, Melton M.
    Curr Med Res Opin; 2007 Jun; 23(6):1341-9. PubMed ID: 17594775
    [Abstract] [Full Text] [Related]

  • 13. Comparison of the effect of alendronate on lumbar bone mineral density and bone turnover in men and postmenopausal women with osteoporosis.
    Iwamoto J, Takeda T, Sato Y, Uzawa M.
    Clin Rheumatol; 2007 Feb; 26(2):161-7. PubMed ID: 16565894
    [Abstract] [Full Text] [Related]

  • 14. Determinants of one-year response of lumbar bone mineral density to alendronate treatment in elderly Japanese women with osteoporosis.
    Iwamoto J, Takeda T, Sato Y, Uzawa M.
    Yonsei Med J; 2004 Aug 31; 45(4):676-82. PubMed ID: 15344210
    [Abstract] [Full Text] [Related]

  • 15. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
    Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM, Fracture Intervention Trial Long-Term Extension Research Group.
    J Bone Miner Res; 2004 Aug 31; 19(8):1259-69. PubMed ID: 15231012
    [Abstract] [Full Text] [Related]

  • 16. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
    Bonnick S, De Villiers T, Odio A, Palacios S, Chapurlat R, DaSilva C, Scott BB, Le Bailly De Tilleghem C, Leung AT, Gurner D.
    J Clin Endocrinol Metab; 2013 Dec 31; 98(12):4727-35. PubMed ID: 24064689
    [Abstract] [Full Text] [Related]

  • 17. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.
    Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, Krege JH, Krohn K, Warner MR.
    Arthritis Rheum; 2009 Nov 31; 60(11):3346-55. PubMed ID: 19877063
    [Abstract] [Full Text] [Related]

  • 18. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
    Ettinger B, San Martin J, Crans G, Pavo I.
    J Bone Miner Res; 2004 May 31; 19(5):745-51. PubMed ID: 15068497
    [Abstract] [Full Text] [Related]

  • 19. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.
    Bone; 2007 Jul 31; 41(1):122-8. PubMed ID: 17468062
    [Abstract] [Full Text] [Related]

  • 20. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E, Lyritis GP, Kosmidis C, Galanos A, Andypas G, Chorianopoulos K, Giagiosis A, Iliadou K, Karagianis A, Katsimichas K, Koskinas A, Matsouka K.
    Clin Rheumatol; 2005 Jun 31; 24(3):232-8. PubMed ID: 15647969
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.